Pfizer announced that it will reduce its Swiss workforce from about 300 employees to roughly 70 by the end of 2025, cutting approximately 230 jobs. The move is part of a multi‑year cost‑realignment program that aims to deliver $4.5 billion in savings by year‑end and $7.7 billion by 2027.
The Swiss plant, which supports manufacturing of several key products, will be streamlined to focus on high‑margin operations. The decision follows pressure from the Inflation Reduction Act, which is tightening Medicare pricing, and the impending patent expirations of blockbuster drugs such as Eliquis and Ibrance, which are expected to erode revenue in the coming years.
Management said the job cuts will free up capital that can be redirected toward Pfizer’s oncology pipeline and its growing obesity portfolio. The company has recently completed the acquisition of Seagen and is in advanced talks to acquire Metsera, moves that underscore its commitment to high‑growth therapeutic areas.
The cost‑cutting program has already produced a $0.24 EPS beat in Q3 2025, driven by disciplined spending and a favorable product mix. The company’s full‑year 2025 EPS guidance was raised to $3.00‑$3.15 from $2.90‑$3.10, reflecting confidence that the savings program will continue to deliver value.
Analysts noted that the Swiss layoffs are a tangible step in Pfizer’s broader effort to protect margins amid pricing headwinds and patent cliffs. While the cuts are painful for employees, they are viewed as a necessary adjustment to maintain profitability and fund future growth initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.